By Professor David Goldstein

Journal articles

GOLDSTEIN D; MILLIKEN S NM; LEWIS C; HOY J; THOMSON B; DOLAN G; RYAN S; SARR A; COOPER DA, 1994, 'FILGRASTIM (r-metHuG-CSF, Amgen), CEOP AND ANTIRETROVIRAL THERAPY IN HIV- RELATED NON-HODGKINS LYMPHOMA (NHL)', AIDS, 8, pp. S46 - S46, http://dx.doi.org/10.1097/00002030-199411004-00179

D G; E T; D C; H G; M N; P H; M O; S M; S P; D H; D C, 1994, 'PHASE I A/B TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER IN ASYMPTOMATIC HTV POSITIVE INDIVIDUALS', AIDS, 8, pp. S14 - S14, http://dx.doi.org/10.1097/00002030-199411004-00054

Tindall B; Carr A; Goldstein D; Penny R; Cooper DA, 1993, 'Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response [1]', AIDS, 7, pp. 127 - 128, http://dx.doi.org/10.1097/00002030-199301000-00020

Lewis CR; Segelov E; Goldstein D; Friedlander ML, 1993, 'Chemotherapy made easier.', Australian and New Zealand Journal of Medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x

Nolten WE; Goldstein D; Lindstrom M; Mckenna MV; Carlson IH; Trump DL; Schiller J; Borden EC; Ehrlich EN, 1993, 'Effects of Cytokines on the Pituitary–Adrenal Axis in Cancer Patients', Journal of Interferon Research, 13, pp. 349 - 357, http://dx.doi.org/10.1089/jir.1993.13.349

Gibson DFC; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC, 1993, 'Human recombinant interferon-βSER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse', Breast Cancer Research and Treatment, 25, pp. 141 - 150, http://dx.doi.org/10.1007/BF00662139

GOLDSTEIN D; KAUFMANN M, 1992, 'NOVEL APPROACHES TO THE MANAGEMENT OF GYNECOLOGIC MALIGNANCIES - CHAIRMENS PREFACE - PROCEEDINGS OF A SATELLITE SYMPOSIUM HELD IN CAIRNS, AUSTRALIA, ON 22 SEPTEMBER 1991', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2, pp. 1 - 1, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992KF21500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smalley RV; Goldstein D; Bulkowski D; Hannon C; Buchler D; Knudsen C; Tuttle RL, 1992, 'A phase II study of crisnatol mesylate in patients with ovarian carcinoma', Investigational New Drugs, 10, pp. 107 - 112, http://dx.doi.org/10.1007/BF00873127

Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC, 1992, 'Absence of Biological Effects of Orally Administered Interferon-βser', Journal of Interferon Research, 12, pp. 411 - 413, http://dx.doi.org/10.1089/jir.1992.12.411

Greiner JW; Guadagni F; Goldstein D; Smalley RV; Borden EC; Simpson JF; Molinolo A; Schlom J, 1992, 'Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells', Journal of Clinical Oncology, 10, pp. 735 - 746

Greiner JW; Guadagni F; Borden EC; Ritts RE; Goldstein D; LoBuglio AF; Schlom J, 1992, 'EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA', Journal of Immunotherapy, 11, pp. 126 - 126, http://dx.doi.org/10.1097/00002371-199202000-00021

Greiner JW; Guadagni F; Goldstein D; Borden EC; Ritts RE; Witt P; LoBuglio AF; Saleh MN; Schlom J, 1991, 'Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons', Cancer Research, 51, pp. 4155 - 4163

Goldstein D; Lewis C, 1991, 'Advances in drug delivery and targeting', Current Opinion in Oncology, 3, pp. 1096 - 1104, http://dx.doi.org/10.1097/00001622-199112000-00019

Goldstein D; O'Leary M; Mitchen J; Borden EC; Wilding G, 1991, 'Effects of interferon βser and transforming growth factor β on prostatic cell lines', Journal of Urology, 146, pp. 1173 - 1177, http://dx.doi.org/10.1016/S0022-5347(17)38034-5

Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR; Leung PE; Levitt D; Sondel PM, 1991, 'Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom', Cancer Investigation, 9, pp. 35 - 48, http://dx.doi.org/10.3109/07357909109032798

Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC, 1990, 'Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-α2', Breast Cancer Research and Treatment, 15, pp. 95 - 101, http://dx.doi.org/10.1007/BF01810781

Goldstein D; Cheuvart B; Trump DL; Shiraki M; Comis RL; Tormey DC; Harris JE; Borden EC, 1990, 'Phase II trial of carboplatin in soft-tissue sarcoma', American Journal of Clinical Oncology Cancer Clinical Trials, 13, pp. 420 - 423, http://dx.doi.org/10.1097/00000421-199010000-00011

Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY, 1990, 'Phase I studies of recombinant interferon-gamma.', J Biol Response Mod, 9, pp. 185 - 193, https://www.ncbi.nlm.nih.gov/pubmed/2160521

GOLDSTEIN D; SOSMAN JA; HANK JA; WEILHILLMAN G; MOORE KH; BORCHERT A; BECHHOFER R; STORER B; KOHLER PC; LEVITT D; SONDEL PM, 1989, 'REPETITIVE WEEKLY CYCLES OF INTERLEUKIN-2 - EFFECT OF OUTPATIENT TREATMENT WITH A LOWER DOSE OF INTERLEUKIN-2 ON NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED KILLER ACTIVITY', CANCER RESEARCH, 49, pp. 6832 - 6839

Goldstein D; Sielaff KM; Stores BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC, 1989, 'Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine', Journal of the National Cancer Institute, 81, pp. 1061 - 1068, http://dx.doi.org/10.1093/jnci/81.14.1061

Guadagni F; Schlom J; Johnston WW; Szpak CA; Goldstein D; Smalley R; Simpson JF; Borden EC; Pestka S; Greiner JW, 1989, 'Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells', Journal of the National Cancer Institute, 81, pp. 502 - 512, http://dx.doi.org/10.1093/jnci/81.7.502

Goldstein D; Bushmeyer SM; Witt PL; Jordan VC; Borden EC, 1989, 'Effects of Type I and II Interferons on Cultured Human Breast Cells: Interaction with Estrogen Receptors and with Tamoxifen', Cancer Research, 49, pp. 2698 - 2702

Goldstein D; Levi JA; Woods RL; Russell J; Morgan J; Kerestes Z, 1989, 'Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy', Oncology Switzerland, 46, pp. 105 - 108, http://dx.doi.org/10.1159/000226695

Laszlo J; Goldstein D, 1988, 'The doctor's dilemma (the nurse's Waterloo)', Cancer Investigation, 6, pp. 361 - 363, http://dx.doi.org/10.3109/07357908809080660

Goldstein D; Laszlo J, 1988, 'The role of interferon in cancer therapy: A current perspective', CA A Cancer Journal for Clinicians, 38, pp. 258 - 277, http://dx.doi.org/10.3322/canjclin.38.5.258

Triozzi PL; Goldstein D; Laszlo J, 1988, 'Contributions of benzodiazepines to cancer therapy.', Cancer Invest, 6, pp. 103 - 111, http://dx.doi.org/10.3109/07357908809077033

Goldstein D; Kelly R; Ralston M; Penny R; Hayes J, 1987, 'Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma', Medical Oncology and Tumor Pharmacotherapy, 4, pp. 101 - 105, http://dx.doi.org/10.1007/BF02934947

Goldstein D; Gockerman J; Tso CY; Hood LE, 1987, 'Effects of 7-Interferon on the Endocrine System: Results from a Phase I Study', Cancer Research, 47, pp. 6397 - 6401

Goldstein D; Laszlo J, 1986, 'Interferon Therapy in Cancer: From Imaginon to Interferon', Cancer Research, 46, pp. 4315 - 4329

Geczy CL; Ryan J; Walsh J; Goldstein D, 1986, 'Lymphokine‐induced monocyte procoagulant activity is depressed in patients with advanced malignancies', International Journal of Cancer, 37, pp. 677 - 682, http://dx.doi.org/10.1002/ijc.2910370506

Laszlo J; Goldstein D; Vugrin D; Hood L; Tso CY, 1986, 'Does maintenance therapy with alpha interferon stabilize cancer growth? A pilot study.', J Biol Response Mod, 5, pp. 294 - 299, https://www.ncbi.nlm.nih.gov/pubmed/3734845

Goldstein D, 'Life on Display: Revolutionizing US Museums of Science and Natural History in the Twentieth Century', WINTERTHUR PORTFOLIO-A JOURNAL OF AMERICAN MATERIAL CULTURE, 50, pp. 90 - 91, http://dx.doi.org/10.1086/687168

Conference Papers

Hosen SMZ; Xu Z; Mekapogu AR; Perera C; Goldstein D; Pirola R; Wilson J; Buckley BJ; Ranson M; Apte M, 2023, 'Inhibition of urokinase plasminogen activator combined with gemcitabine enhances immune regulation and eradicates metastasis in pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 31 - 32

Huang S; Jacinto J; O'Sullivan B; Su J; Xu W; Spreafico A; Goldstein D; Waldron J, 2022, 'Clinical presentation and outcome of HPV-positive nasopharyngeal carcinoma in a North American cohort', in ORAL ONCOLOGY, ELSEVIER, NETHERLANDS, Amsterdam, presented at 4th International Symposium on HPV Infection in Head and Neck Cancer - Latest Advances in Biomarker-Driven Management, NETHERLANDS, Amsterdam, 10 November 2022 - 11 November 2022, http://dx.doi.org/10.1016/j.oraloncology.2022.106168

Kokkinos J; Sharbeen G; Haghighi KS; Youkhana J; Raina A; Pitiyarachchi O; Truong Q; Wenholz D; Laczka O; Kumar N; Goldstein D; Phillips PA, 2022, 'CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, pp. 161 - 161, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 13 September 2022 - 16 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000899825600205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Li T; Timmins H; Trinh T; Horvath L; Harrison M; Grimison P; Kiernan M; Goldstein D; Park S, 2022, 'LONGITUDINAL TRAJECTORIES OF CLINICAL, NEUROLOGICAL AND PATIENT-REPORTED CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY FOLLOWING TREATMENT COMPLETION', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. S169 - S169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000822950200350&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Elhofy A; Kelley WJ; Chen J; Murthy T; Xu Q; Boyne M; Goldstein D, 2022, 'Nanoparticles divert monocytes away from the lungs to improve outcomes after influenza virus infection in aged mice', in JOURNAL OF IMMUNOLOGY, AMER ASSOC IMMUNOLOGISTS, OR, Portland, presented at Immunology Meeting, OR, Portland, 06 May 2022 - 10 May 2022, http://dx.doi.org/10.4049/jimmunol.208.Supp.126.26

Evans E; Wascher M; Goldstein D; Krane C, 2022, 'Multiple Freeze-thaw Cycles in Cope's Gray Treefrog Dryophytes chrysoscelis Reveal Novel Physiological, Biochemical, and Morphological Insights into Vertebrate Freeze Tolerance', in FASEB JOURNAL, WILEY, PA, Philadelphia, presented at Experimental Biology Meeting (EB), PA, Philadelphia, 02 April 2022 - 05 April 2022, http://dx.doi.org/10.1096/fasebj.2022.36.S1.R4116

Tyrrell D; Goldstein D, 2022, 'AGE-ASSOCIATED GRANZYME K-EXPRESSING CD8+T-CELLS ENHANCE ATHEROSCLEROSIS IN MICE', in INNOVATION IN AGING, OXFORD UNIV PRESS, pp. 196 - 196

Colvin A; Baugh E; Babbush K; Adriano T; Benesh G; Torpey ME; Nosrati A; DeWan AT; Leal SM; Goldstein D; Cohen S; Petukhova L, 2022, 'Distribution of hidradenitis suppurativa monogenic etiologies in a racially diverse specialty clinic cohort', in JOURNAL OF INVESTIGATIVE DERMATOLOGY, ELSEVIER SCIENCE INC, pp. S80 - S80

Mahfouz F; Li T; Timmins H; Goldstein D; Park S, 2022, 'IMPACT OF PAIN ON SYMPTOM BURDEN IN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. S86 - S86

Papadopoulos LA; Georgiou CL; Kee D; Reece C; Helen K; Allison B; Javier H; Turner M; Goldstein D; Scott C, 2022, 'Patient vignettes reflecting the impact of The Australian Rare Cancer Portal on patients with Rare Cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 182 - 183

Lemech C; Dredge K; Bampton D; Hammond E; Clouson A; Waterhouse N; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341

Lemech C; Dredge K; Bampton D; Hammond E; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340

Jacinto JKM; Huang SH; Su J; Kim J; O'Sullivan B; Ringash J; Cho J; Hope AJ; Bratman S; Giuliani M; Hosni A; Hahn E; Spreafico A; Hansen A; Goldstein D; Tong L; Perez-Ordonez B; Weinreb I; Xu W; Waldron J, 2021, 'Clinical Behavior and Outcome of HPV-Positive Nasopharyngeal Carcinoma', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, pp. E384 - E385

Scott CL; Lim R; Kee D; Georgiou C; Caldwell R; Papadopoulos L; Krasovitsky MS; Tay R; Bourne A; Vandenberg C; Dall G; Shield-Artin K; Carmagnac A; Ratnayak G; Tram J; Zhou W; Bedo J; Penington J; Zhu L; Vissers J; Thomas D; Grimmond S; Wakefield M; Papenfuss T; Barke H; Goldstein D, 2021, 'Delivering personalized care and research for rare cancers in the increasingly genomic world?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 92, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500102&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bartley N; Best MC; Biesecker BB; Fisher A; Goldstein D; Meiser B; Thomas DM; Ballinger ML; Butow P, 2021, 'Effectively communicating comprehensive tumour genomic profiling results: Mitigating uncertainty for advanced cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 180 - 180, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500295&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

O'Sullivan B; Huang SH; Hahn E; Gullane P; Irish J; Su J; Tong L; de Almeida J; Gilbert RW; Brown D; Witterick I; Vescan A; Montero E; Gentili F; Catton C; Chung P; Chepeha DB; Goldstein D; Xu W; Hosni A, 2021, 'High Local Control Following Pre-Operative Radiotherapy for Adult Deep Soft Tissue Sarcoma of the Head and Neck', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, pp. S41 - S42

Said BI; Ailles L; Huang SH; Xu W; Keshavarzi S; Bratman SV; Cho J; Giuliani ME; Hahn E; Kim J; O'Sullivan B; Ringash JG; Waldron JN; Spreafico A; De Almeida J; Chepeha DB; Irish J; Goldstein D; Hope AJ; Hosni A, 2021, 'Patient-Derived Xenograft Engraftment Predicts Oral Cavity Cancer Outcomes', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, pp. E391 - E392

Vatter S; Schlub TE; Napier CE; Best MC; Bartley N; Juraskova I; Meiser B; Ballinger ML; Biesecker BB; Goldstein D; Thomas DM; Butow P, 2021, 'Psychological outcomes in advanced cancer patients after receiving genomic tumour profiling results', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 198 - 198, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500332&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page